About Pfizer, Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer, Inc. (PFE) is a Healthcare company in the Drug Manufacturers - General industry with a market capitalisation of $158B. The stock trades at 36.47x trailing earnings and yields 6.2%.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $158B
- P/E ratio
- 36.47
- Forward P/E
- 9.57
- EPS (TTM)
- $0.76
- Revenue (TTM)
- $63.7B
- Free cash flow
- $12.5B
- Profit margin
- 6.8%
- Dividend yield
- 6.2%
- Beta
- 0.30
- Shares outstanding
- 5.7B
Financial health: Weak3.6/10
2 strengths, 5 concerns. Weakest points: net debt vs cash flow, return on equity, earnings growth and 2 more.
- Debt to equity: 0.75 (Watch, benchmark < 0.5) — Debt of 0.75x equity is moderate against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: 6.0y (Concern, benchmark < 4 years) — Net debt of $54.3B is 6.0x annual free cash flow — about 6 years of cash flow to repay.
- Current ratio: 1.16 (Watch, benchmark > 1.5) — Short-term assets cover 1.16x short-term liabilities, against Graham's 1.5x floor. It has been broadly flat over the last 4 years.
- Return on equity: 5.0% (Concern, benchmark > 15%) — Earns 5.0% on shareholder equity, well short of the > 15% mark.
- Gross margin: 74.7% (Strong, benchmark > 40%) — Keeps 74.7% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 6.8% (Watch, benchmark > 10%) — Turns 6.8% of revenue into profit, short of the > 10% mark.
- Free cash flow: $9.1B (Strong, benchmark positive) — Generated $9.1B of free cash flow after capital spending. It has deteriorated over the last 4 years.
- Revenue growth: 2.6% (Watch, benchmark > 10%) — Revenue changed 2.6% year on year, short of the > 10% mark.
- Earnings growth: -3.2% (Concern, benchmark > 10%) — Earnings changed -3.2% year on year, well short of the > 10% mark.
- PEG ratio: 12.68 (Concern, benchmark < 1) — At 12.68, the price looks expensive relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 226.3% (Concern, benchmark < 60%) — Pays out 226.3% of earnings as dividends — above the level usually considered sustainable.